Antisense Pharma gets added patent protection for trabedersen until 2026; raises 13 million euros

The European Patent Office has granted German biopharmaceutical company Antisense Pharma additional patent protection for the use of its flagship product trabedersen until 2026. This gives Antisense a comprehensive marketing exclusivity for the use of this drug within the settings of tumor-illnesses, central nervous system diseases and immunosuppression, taking into consideration the effective dose.

Trabedersen is currently in Phase III of the clinical study for the indication of malignant brain tumours (WHO Grade III). Also, a Phase II/III Study into advanced pancreatic cancer is being prepared at the moment.

Furthermore, the company announced a recently-completed round of financing. MIG Fonds and the Global Asset Fund have once again invested in Antisense and have confirmed their confidence in the enormous potential of the firm's products. The company's management and private investors also took part in the investment of a total of 13 million euros ($17.7 million). The capital which has just been raised is to be used particularly for the further clinical development of trabedersen.